Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / GSK===ViiV Healthcare
Entity

GSK===ViiV Healthcare

Tracked across 1 events · 7 articles · First seen Feb 25, 2026 · Last active Feb 27, 2026

Sentiment
80
Attention
4
Events
1
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 80
Tech
ViiV Healthcare's Lotivibart HIV Treatment Shows Positive Phase IIb Data
GSK===ViiV Healthcare announced positive 12-month interim efficacy and tolerability data from its phase IIb EMBRACE study for lotivibart, an ultra long-acting HIV treatment. This reinforces the potential of lotivibart and supports further study progression, enhancing GSK===ViiV Healthcare's position in HIV treatment.
Feb 25, 2026 · 7 articles
Relationships (2)
Shionogi shareholder ↔ GSK===ViiV Healthcare Shionogi is a shareholder in GSK===ViiV Healthcare and is increasing its investm
Kimberly Smith (scientist) Head of Research & Development ↔ GSK===ViiV Healthcare Kimberly Smith is the Head of Research & Development at GSK===ViiV Healthcare.
NEWSDESK
Track GSK===ViiV Healthcare live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.